All In Biotech

Drug Trial Radar · NCT04659239

The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19

A Randomized, Double-Blinded, Placebo Controlled Phase III Clinical Trial of SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in Adults Aged 18 Years and Above

Last checked: Nov 20, 2026Latest source record: Feb 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 34,020 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

34,020

Planned (sponsor's estimate)

Start

Jan 28, 2021

Primary completion

Sep 2021

Study completion Jul 2022

Sponsor

Lead sponsor
Chinese Academy of Medical SciencesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blinded, placebo controlled phase III clinical trial to evaluate the efficacy, safety and immunogenicity of SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in adults aged 18 years and above after 2-dose schedule.

Conditions

  • COVID-19

Interventions

  • Inactivated SARS-CoV-2 Vaccine (Vero cell)Biological

    The inactivated SARS-CoV-2 vaccine (vero cell) was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.

  • PlaceboBiological

    The placebo was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of COVID-19 cases after two-doses of vaccinationTime frame: From 14 days after the second dose to 1 year after the second dose.
  2. The incidence of solicited AEs.Time frame: 7 days after each dose

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • CEMEC Pesquisa Clinica

    São Bernardo do Campo, São Paulo, Brazil

  • Hospital Sungai Buloh

    Sungai Buloh, Selangor, Malaysia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.